Modified · Segments of business

The Innovative Medicine segment is focused on the following therapeutic areas: Oncology (e.g., prostate cancer, hematologic malignancies, lung cancer and bladder cancer), Immunology (e.g., rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders and schizophrenia), Oncology Pulmonary Hypertension (e.g., prostate cancer, hematologic malignanciesPulmonary Arterial Hypertension), lung cancer and bladder cancerInfectious Diseases (e.g., HIV/AIDS), and Cardiovascular and Metabolism (e.g., thrombosis, diabetes and macular degeneration) and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. Key products in the Innovative Medicine segment include: REMICADECARVYKTI (infliximabciltacabtagene autoleucel), a treatment chimeric antigen receptor (CAR)-T-cell therapy for a numberthe treatment of immune-mediated inflammatory diseasespatients with relapsed/refractory multiple myeloma; SIMPONIDARZALEX (golimumabdaratumumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritismultiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), active psoriatic arthritis, active ankylosing spondylitis a treatment for multiple myeloma and moderately active to severely active ulcerative colitislight chain (AL) Amyloidosis; SIMPONI ARIA ERLEADA (golimumabapalutamide), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and oldera next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; STELARARYBREVANT (ustekinumabamivantamab), a treatment fully-human bispecific antibody for adults and children with moderate to severe plaque psoriasiswith EGFR-mutated non-small cell lung cancer and LAZCLUZE (lazertinib), for adults with active psoriatic arthritis, an oral, brain-penetrant EGFR tyrosine kinase inhibitor for adults with moderately to severely active Crohn's disease non-small cell lung cancer; RYBREVANT FASPRO (amivantamab and treatment of moderately to severely active ulcerative colitishyaluronidase-lpuj), a subcutaneous therapy for patients with non-small cell lung cancer; TREMFYATALVEY (guselkumabtalquetamab-tgvs), a treatment bispecific antibody for adults with moderate to severe plaque psoriasis and active psoriatic arthritis and ulcerative colitisrelapsed or refractory multiple myeloma who have received at least four prior lines of therapy; EDURANTTECVAYLI (rilpivirineteclistamab-cqyv), PREZISTA (darunavir) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV) in combination with other antiretroviral products and SYMTUZA a bispecific antibody for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy; ZYTIGA (darunavir/cobicistat/emtricitabine/tenofovir alafenamideabiraterone acetate), a once-daily single tablet regimen treatment for the treatment of HIVpatients with prostate cancer; CONCERTAREMICADE (methylphenidate HClinfliximab) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitatea number of immune-mediated inflammatory diseases; SIMPONI (golimumab), for thea subcutaneous treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA/TREVICTA (paliperidone palmitate)for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for at least four months; SPRAVATO (Esketamine), a nasal sprayadults with moderate to severe rheumatoid arthritis, used along with an oral antidepressant, to treat adults with treatment-resistant depression active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (TRDpJIA) and depressive symptoms in adults with major depressive disorderin people 2 years of age and older; STELARA (MDDustekinumab) with suicidal thoughts or actions; CARVYKTI (ciltacabtagene autoleucel), a treatment for adults and children with moderate to severe plaque psoriasis, a chimeric antigen receptor (CAR)-T-cell therapyfor adults with active psoriatic arthritis, for the adults with moderately to severely active Crohn's disease and treatment of patients with relapsed/refractory multiplemoderately to severely active